Heterogeneity of ORs between BRCA1 and BRCA2 were shown in ovarian (I2, 90.9%) and prostate cancer (I2, 77.4%) (Table 2).32 We also observed an association with lymphoma and lung cancer for BRCA1 and endometrial, cervical, kidney, and liver cancers for BRCA2 (Table 2). This evidence concerns the gene BRCA1 and lymphoma.